Connect with us

Spread & Containment

Thanks To Omicron, 2022’s Price Increases Will Be More Painful Than Anything We’ve Experienced Before

Thanks To Omicron, 2022’s Price Increases Will Be More Painful Than Anything We’ve Experienced Before

Authored by Michael Snyder via The Economic Collapse blog,

Most people simply do not understand that we really are moving into a long-term.

Published

on

Thanks To Omicron, 2022's Price Increases Will Be More Painful Than Anything We've Experienced Before

Authored by Michael Snyder via The Economic Collapse blog,

Most people simply do not understand that we really are moving into a long-term economic emergency.  So much of the economic optimism that fueled rallies in the financial markets throughout 2022 was based on a belief that the COVID pandemic would soon be brought to an end.  Well, that obviously has not happened.  After everything that has been done, the COVID pandemic in the United States is now worse than ever.  In fact, on Wednesday there were 465,470 newly confirmed cases in the United States alone.  That shattered the old daily record by more than 100,000.  The Omicron variant is spreading like wildfire, and this is going to cause mass panic during the early stages of 2022.

It doesn’t take a genius to figure out what this is going to mean for the economy.  Fear of Omicron is going to weigh heavily on production all over the globe, and so there will be less stuff available for us to buy.  Meanwhile, fear of Omicron is also likely to make our supply chain crisis even worse.  It will be even more of a challenge to move goods around the globe in a timely manner, and that is going to mean even more empty shelves.

But thanks to the reckless policies of the Biden administration and the Federal Reserve, Americans have lots and lots of money in their pockets.  All of those dollars are going to be chasing declining levels of goods and services, and that is going to result in hair-curling inflation.

Of course what we have already experienced has been painful enough.  Earlier today, the top moderator of one of the most popular discussion forums on the Internet posted this

Just bought 2 prime ribeyes for $64…

I was shocked!

That’s got to be double what I used to pay.

Meat prices are getting really crazy, but they are only going to go even higher.

The same thing can be said for all other food prices too.  Even before Omicron came along, major companies all over the country were preparing major price hikes for 2022.

For example, the maker of Oreos and Ritz crackers has announced that all of their prices will be going up 6 to 7 percent next year…

Mondelez International, which makes snacks including Oreo cookies and Ritz crackers, will increase prices by 6% to 7% in January, the company said last month.

Other food producers will be implementing much larger price increases.  When the Wall Street Journal reported that Kraft Heinz would be lifting prices by as much as 20 percent in 2022, that definitely alarmed a lot of people…

According to the Wall Street Journal, Kraft Heinz’s price increases were among the most dramatic heading into 2022, with some items going up as much as 20%; the price of the company’s Grey Poupon mustard, for example, will increase between 6% to 13%.

And it is being reported that General Mills will also be raising prices by around 20 percent

A “major regional wholesale supplier” leaked to CNN a letter that General Mills sent retailers to inform them that the price of some products could increase by as much as 20% starting in mid-January. This would be on the extreme end, but that high rate is certainly concerning.

So get ready to pay a whole lot more for cereal.

Even prices at Dollar Tree will be going from $1.00 to $1.25 in a few months.

Sadly, this is just the beginning, and even Goldman Sachs is now admitting that “the inflation overshoot will likely get worse”

In a recent analyst note to clients, Goldman Sachs economists warned that pandemic-induced disruptions in the global supply chain – which have caused congestion in ports and warehouses nationwide – could last longer than expected as surging demand struggles to keep up, meaning that inflation metrics will remain “quite high for much of next year.”

“It is now clear that this process will take longer than initially expected, and the inflation overshoot will likely get worse before it gets better,” they wrote.

The optimists at Goldman Sachs believe that things will eventually improve, but that is because they still have faith that the gurus at the Federal Reserve can magically make everything better somehow.

But the Fed only has two “solutions” to any crisis.

They can cut interest rates, but they have already been pushed all the way to the floor.

They can also pump more money into the system, and they have been doing this for years.  But now all of that money pumping has created a raging inflation nightmare, and they don’t know how to put the fire out.

They could try to get inflation under control by raising rates, but that would severely hurt the economy at a time when we are plunging into a fresh crisis because of Omicron.

So now the Fed finds itself in a very tough spot, and Nouriel Roubini is warning that this could lead to big trouble in 2022

As long as central banks were in unconventional policy mode, the party could keep going. But the asset and credit bubbles may deflate in 2022 when policy normalization starts. Moreover, inflation, slower growth, and geopolitical and systemic risks could create the conditions for a market correction in 2022. Come what may, investors are likely to remain on the edge of their seats for most of the year.

There will be no easy way out for the Federal Reserve this time.

When push comes to shove, Fed officials will always resort to printing more money, and that is going to set the stage for the sort of economic scenarios that I have described in my books.

It looked like 2022 was going to be really bad even before Omicron came along, and now the outlook for next year is downright horrifying.

Fear is poison for any economic system, and the level of fear in this country just continues to rise with each passing day.

*  *  *

It is finally here! Michael’s new book entitled “7 Year Apocalypse” is now available in paperback and for the Kindle on Amazon.

Tyler Durden Fri, 12/31/2021 - 10:30

Read More

Continue Reading

Spread & Containment

VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…

By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
Business Update
FORTRESS Trial Fully Enrolled; Topline Results in September 2022
On…

Published

on

By David Bautz, PhD

NASDAQ:VIRI

READ THE FULL VIRI RESEARCH REPORT

Business Update

FORTRESS Trial Fully Enrolled; Topline Results in September 2022

On April 28, 2022, Virios Therapeutics, Inc. (NASDAQ: VIRI) announced that it has completed enrollment of 425 fibromyalgia patients into the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1) trial, a randomized, double blind, placebo controlled study of IMC-1. The primary endpoint of the trial is reduction in pain and secondary endpoints include change in fatigue, sleep disturbance, global health status, and patient functionality (NCT04748705). An outline of the trial is shown below.

In parallel with the FORTRESS trial, Virios is continuing the chronic toxicology studies of IMC-1 in two animal species. The results of these studies are required by regulators before Virios will be allowed to dose patients for one year or more, which is the plan for the Phase 3 program. The results of the chronic toxicology studies should be known around the time of the completion of the FORTRESS trial, thus the company should be able to move into a final Phase 3 program following completion of the current study, pending positive results.

Testing Combination Antiviral Therapy for the Treatment of Long COVID

In February 2022, Virios announced a collaboration with the Bateman Horne Center (BHC) to test combination antiviral therapy for the treatment of Long COVID. Following an infection with SARS-CoV-2, the virus that causes COVID-19, approximately 30% of patients will experience symptoms that last for weeks or months, which is referred to as Long COVID. The range of symptoms varies from patient to patient, however the most commonly reported (from a recent meta analysis) were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%) (Lopez-Leon et al., 2021).

The main theories for what might be causing ...

Full story available on Benzinga.com

Read More

Continue Reading

Spread & Containment

Type-I interferon stops immune system ‘going rogue’ during viral infections

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how…

Published

on

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

Credit: Georgia Kirkos/McMaster University

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

 

They have discovered how Type I interferon (IFN) stops the immune system ‘going rogue’ and attacking the body’s own tissues when fighting viral infections, including COVID-19.

 

Their paper was published in the journal PLOS Pathogens today.

  

Senior author Ali Ashkar said IFN is a well-known anti-viral signalling molecule released by the body’s cells that can trigger a powerful immune response against harmful viruses.

 

“What we have found is that it is also critical to stop white blood cells from releasing protease enzymes, which can damage organ tissue. It has this unique dual function to kick start an immune response against a viral infection on the one hand, as well as restrain that same response to prevent significant bystander tissue damage on the other,” he said.

 

The research team investigated IFN’s ability to regulate a potentially dangerous immune response by testing it on both flu and the HSV-2 virus, a highly prevalent sexually transmitted pathogen, using mice. Data from COVID-19 patients in Germany, including post-mortem lung samples, was also used in the study.

 

“For many viral infections, it is not actually the virus that causes most of the tissue damage, it is our heightened immune activation towards the virus,” said Ashkar, a professor of medicine at McMaster.

  

First co-author of the study and PhD student Emily Feng said: “Our body’s immune response is trying to fight off the virus infection, but there’s a risk of damaging innocent healthy tissue in the process. IFNs regulates the immune response to only target tissues that are infected.

 

“By discovering the mechanisms the immune system uses that can inadvertently cause tissue damage, we can intervene during infection to prevent this damage and not necessarily have to wait until vaccines are developed to develop life-saving treatments,” she added.

 

“This applies not just to COVID-19, but also other highly infectious viruses such as flu and Ebola, which can cause tremendous and often life-threatening damage to the body’s organs,” said first study co-author Amanda Lee, a family medicine resident. 

 

Ashkar said the release of harmful proteases is the result of a ‘cytokine storm’, which is life-threatening inflammation sometimes triggered by viral infections. It has been a common cause of death in patients with COVID-19, but treatment has been developed to prevent and suppress the cytokine storm.

 

Ashkar said that steroids like dexamethasone are already used to rein in an extreme immune response to viral infections. The authors used doxycycline in their study, an antibiotic used for bacterial infections and as an anti-inflammatory agent, inhibits the function of proteases causing the bystander tissue damage.

 

Lee added: “This has the potential in the future to be used to alleviate virus-induced life-threatening inflammation and warrants further research.” 

 

The study was funded by the Canadian Institutes of Health Research.

 

-30-

 

Editors:

Pictures of Ali Ashkar and Emily Feng may be found at https://bit.ly/3wmSw0D

  

 

 


Read More

Continue Reading

Spread & Containment

mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World…

Published

on

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

Credit: Carlos Reusser Monsalvez, Flickr (CC0, https://creativecommons.org/publicdomain/zero/1.0/)

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

By March 2022, COVID-19 had caused over 450 million confirmed infections and six million reported deaths. The first vaccines approved in the US and Europe that protect against serious infection are Pfizer-BioNTech and Moderna, which deliver genetic code, known as mRNA, to the bodies’ cells, whereas Oxford/AstraZeneca and J&J/Janssen are viral vector vaccines that use a modified version of a different virus — a vector — to deliver instructions to our cells. Three vaccines are delivered as two separate injections a few weeks apart, and J&J/Janssen as a single dose.

Marit J. van Gils at the University of Amsterdam, Netherlands, and colleagues, took blood samples from 165 healthcare workers, three and four weeks after first and second vaccination respectively, and for J&J/Janssen at four to five and eight weeks after vaccination. Samples were collected before, and four weeks after a Pfizer-BioNTech booster.

Four weeks after the initial two doses, antibody responses to the original SARS-CoV-2 viral strain were highest in recipients of Moderna, followed closely by Pfizer-BioNTech, and were substantially lower in those who received viral vector vaccines. Tested against the VOCs – Alpha, Beta, Gamma, Delta and Omicron – neutralizing antibodies were higher in the mRNA vaccine recipients compared to those who had viral vector vaccines. The ability to neutralize VOCs was reduced in all vaccine groups, with the greatest reduction against Omicron. The Pfizer-BioNTech booster increased antibody responses in all groups with substantial improvement against VOCs, including Omicron.

The researchers caution that their AstraZeneca group was significantly older, because of safety concerns for the vaccine in younger age groups. As immune responses tend to weaken with age, this could affect the results. This group was also smaller because the Dutch government halted use for a period.

van Gils concludes, “Four COVID-19 vaccines induce substantially different antibody responses.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003991

Citation: van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, et al. (2022) Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 19(5): e1003991. https://doi.org/10.1371/journal.pmed.1003991

 

Author Countries: The Netherlands, United States

 

Funding: This work was supported by the Netherlands Organization for Scientific Research (NWO) ZonMw (Vici grant no. 91818627 to R.W.S., S3 study, grant agreement no. 10430022010023 to M.K.B.; RECoVERED, grant agreement no. 10150062010002 to M.D.d.J.), by the Bill & Melinda Gates Foundation (grant no. INV002022 and INV008818 to R.W.S. and INV-024617 to M.J.v.G.), by Amsterdam UMC through the AMC Fellowship (to M.J.v.G.) and the Corona Research Fund (to M.K.B.), and by the European Union’s Horizon 2020 program (RECoVER, grant no. 101003589 to M.D.d.J). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Read More

Continue Reading

Trending